Weibo Secondary Listing - Needs to Come at a Discount
Weibo plans to raise around US$500-700m in its secondary listing in Hong Kong. In this note, we talk about the deal and its impact.
279 Views
Pre-IPO Hutchmed China Ltd (13.HK) - The Strength and the Concerns
The article analyzed Hutchmed in terms of its business analysis, financial performance, pipeline, comparison with other biotech companies, and also...
262 Views
HutchMed Secondary Listing: HK-ADS Premium/(Discount) Views
HutchMed has launched a $603 million secondary listing on HKEx. In this note, we will look at HutchMed’s potential HK-ADS premium/(discount).
312 Views
HCM Secondary Listing: Not a Good Performer
After its failed listing attempt 2019, today HCM launched its book building to raise USD 590m in its secondary listing in Hong Kong. We look at...
403 Views
China ADRs - A New Act Aims to Put an End to China ADR IPOs
On 27th May 2021, U.S. Senators Marco Rubio and Bob Casey introduced the No IPOs for Unaccountable Actors Act, which aims to prohibit IPO on U.S....
305 Views